Biodesix Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
39.9%projected annual EPS growth
Analyst Coverage
6analysts covering
FY Revenue (est.)
$111Mnext fiscal year
FY EPS (est.)
-$2.96next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Diagnostic Test Volume Quarterly17.8KTarget: Continued volume growth driven by sales force expansion and primary care adoption
Quarterly Total Revenue Quarterly25.6MTarget: Full Year 2026 Guidance of $108 million to $114 million
Gross Margin (GAAP) Quarterly8,400.0%Target: Maintain high-80s percentage through workflow optimization and test mix
Active Sales Representatives Quarterly100.0Target: Add approximately 6 representatives per quarter through 2026
Watch Items
- Primary Care Channel PenetrationTrigger: Primary care test volume falling below 15% of total testsAction: Re-evaluate sales force allocation and marketing materials targeted at primary care physicians.
- Adjusted EBITDA Profitability PathTrigger: Adjusted EBITDA loss widening significantly beyond Q1 2026 levels ($4.1 million loss)Action: Implement stricter cost controls on SG&A and optimize laboratory workflow efficiencies.
- Payer Coverage and Reimbursement RatesTrigger: Rejection or reduction in average revenue per test from major commercial payersAction: Engage market access teams to present additional real-world clinical utility data (e.g., ATS 2026 presentations).
Research as of 19 Jun 2026